Biomarker endpoints for Parkinson’s disease
Supported by:
14 March 2018
ABOUT THIS WEBINAR:
Therapeutic approaches for Parkinson’s disease are either focused on disease modification (a-synuclein or MPTP models) or symptom management (haloperidol or 6-OHDA models). Our scientists have validated available PD models for changes in fine motor skills, L-dopa-induced dyskinesias, drug-induced jaw movements, and non-motor endpoints such as cognition, constipation, and EDS. Additionally, we have also tested dopamine and other neurotransmitter levels in brain compartments of rodent and large animal models via microdialysis sampling.
This webinar provides a comprehensive review of clinically relevant endpoints identified in established and novel animal models of PD that can be used to assess the efficacy of novel disease-modifying and symptom focused therapies.
The rest of this content is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Biomarkers, Drug Discovery, Drug Discovery Processes, In Vitro, In Vivo, Precision medicine, Therapeutics
Related organisations
Charles River Laboratories
